GlassScriptPhysician profile
Michael T Mcavoy
NPI 1700863859
$807.48
in general payments reported to CMS, 2019-2025
10 companies · $250 in 2025
The $250 reported for 2025 was less than what a typical Allergy provider received nationally (typical 2025 total: $1,129).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $176 · 2020: $57.57 · 2021: $13.17 · 2022: $48.86 · 2023: $81.81 · 2024: $180 · 2025: $250.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $293 · Food and Beverage: $218.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $293.23 |
| Food and Beverage | $218.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $160.91 | 2019-2024 | |
| Genentech USA, INC. | $148.84 | 2019 | |
| Sanofi-Aventis U.S. LLC | $146.98 | 2023-2024 | |
| Regeneron Healthcare Solutions, INC. | $117.09 | 2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.25 | 2024-2025 | Eohilia |
| Pfizer INC. | $34.89 | 2019-2023 | |
| Amgen INC. | $34.00 | 2025 | |
| Aimmune Therapeutics, INC. | $27.24 | 2020 | |
| Glaxosmithkline, LLC. | $13.17 | 2021 | |
| Sunovion Pharmaceuticals INC. | $12.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcavoy listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.